ArticleBMC cancer2015

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Hiroki Osumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.